![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Novel HIV PI with High Resistance Barrier
and Potential for Unboosted QD Oral Dosing
|
|
|
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
John O. Link, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan Shapiro, George Stepan, Yujin Wang, Zeng-Yu Yang
Gilead Sciences, Inc., Foster City, CA
WEBCAST: http://www.croiwebcasts.org/console/player/33636?mediaType=slideVideo&
![CROI1](../images/033017/033017-1/CROI1.gif)
![CROI2](../images/033017/033017-1/CROI2.gif)
![CROI3](../images/033017/033017-1/CROI3.gif)
![CROI4](../images/033017/033017-1/CROI4.gif)
![CROI5](../images/033017/033017-1/CROI5.gif)
![CROI6](../images/033017/033017-1/CROI6.gif)
![CROI7](../images/033017/033017-1/CROI7.gif)
![CROI8](../images/033017/033017-1/CROI8.gif)
![CROI9](../images/033017/033017-1/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|